YAPping About Differentiation Therapy in Muscle Cancer
MN Svalina, C Keller – Cancer Cell, 2014
This article is linked to “The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation” (Tremblay, et.al.) which was the basis for Samantha Olson’s article “Cause of Rare Childhood Cancer, Rhabdomyosarcoma, Discovered: May Lead to Treatment in the Future.”
Overcoming a presumed differentiation block in the childhood muscle cancer embryonal rhabdomyosarcoma is often thought to hold promise as an approach to replace cytotoxic chemotherapy with molecularly- targeted differentiation therapies. In this issue of Cancer Cell, Tremblay and colleagues implicate YAP1 and the Hippo signaling pathway in the maintenance of differentiation-arrested and proliferative phenotypes for embryonal rhabdomyosarcoma.
Differentiation therapy for the muscle cancer rhabdomyosarcoma (RMS) has been thought to hold promise for replacing cytotoxic chemotherapy with molecularly targeted therapies. Such a targeted therapy might restore the terminal myogenic differentiation program to the rhabdomyosarcoma cells and (potentially) reduce life-long chemotherapy related sequelae for the patient….
This article is protected by copyright laws and cannot be reproduced in its totality. Please use the Contact Us form to request a copy.